Search

Your search keyword '"Guancial, Elizabeth"' showing total 17 results
Start Over Author "Guancial, Elizabeth" Publication Year Range Last 3 years
17 results on '"Guancial, Elizabeth"'

1. Supplementary Table 4 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

2. Data from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Table 2 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table 1 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 5 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 3 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figures 1 - 4 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure and Table Legends from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 6 from Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Author

Van Allen, Eliezer M., primary, Mouw, Kent W., primary, Kim, Philip, primary, Iyer, Gopa, primary, Wagle, Nikhil, primary, Al-Ahmadie, Hikmat, primary, Zhu, Cong, primary, Ostrovnaya, Irina, primary, Kryukov, Gregory V., primary, O'Connor, Kevin W., primary, Sfakianos, John, primary, Garcia-Grossman, Ilana, primary, Kim, Jaegil, primary, Guancial, Elizabeth A., primary, Bambury, Richard, primary, Bahl, Samira, primary, Gupta, Namrata, primary, Farlow, Deborah, primary, Qu, Angela, primary, Signoretti, Sabina, primary, Barletta, Justine A., primary, Reuter, Victor, primary, Boehm, Jesse, primary, Lawrence, Michael, primary, Getz, Gad, primary, Kantoff, Philip, primary, Bochner, Bernard H., primary, Choueiri, Toni K., primary, Bajorin, Dean F., primary, Solit, David B., primary, Gabriel, Stacey, primary, D'Andrea, Alan, primary, Garraway, Levi A., primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legends from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures 1 - 5, Tables 1 - 2 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 6 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

15. 661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma

Author

Aggen, David, primary, McKean, Meredith, additional, Lakhani, Nehal, additional, Bashir, Babar, additional, Hoffman-Censits, Jean, additional, Alhalabi, Omar, additional, Guancial, Elizabeth, additional, Bowman, Isaac, additional, Tan, Alan, additional, Lingaraj, Trupti, additional, Timothy, Marissa, additional, Ortiz-Otero, Nerymar, additional, Bartolini, Wilmin, additional, Kacena, Katherine, additional, Malek, Karim, additional, Santillana, Sergio, additional, and Luke, Jason, additional

Published
2022
Full Text
View/download PDF

16. Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.

Author

McKean, Meredith, primary, Aggen, David Henry, additional, Lakhani, Nehal J., additional, Bashir, Babar, additional, Luke, Jason J., additional, Hoffman-Censits, Jean H., additional, Alhalabi, Omar, additional, Bowman, Isaac Alex, additional, Guancial, Elizabeth A., additional, Tan, Alan, additional, Lingaraj, Trupti, additional, Timothy, Marissa, additional, Kacena, Katherine, additional, Malek, Karim S., additional, and Santillana, Sergio, additional

Published
2022
Full Text
View/download PDF

17. Frontline immune checkpoint inhibitors in patients ≥ 90 years with advanced urothelial cancer: a single center experience.

Author

Vlachou E, Johnson Ⅲ BA, Guancial E, Lombardo KA, and Hoffman-Censits J

Subjects
Humans, Male, Female, Retrospective Studies, Aged, 80 and over, Neoplasm Staging, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Antibodies, Monoclonal, Humanized therapeutic use, Urologic Neoplasms drug therapy, Urologic Neoplasms pathology, Treatment Outcome, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors adverse effects, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology
Abstract

Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first-line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often not a treatment option for older patients due to comorbidities that increase with age. Despite ICIs being better tolerated compared to traditional chemotherapy little is known about their efficacy and toxicity in patients ≥ 90 years due to the rarity of this population in clinical trials. Our objective was to analyze the efficacy and toxicity of immune checkpoint inhibitors in patients ≥ 90 years., Materials and Methods: We conducted a single center retrospective review of patients ≥ 90 years treated between July 2019 and September 2023 with standard of care ICIs for advanced urothelial cancer., Results: Six patients treated with pembrolizumab were identified. Four (66.7%) were male and mean age was 93.5 years at the time of treatment initiation. Response rate was 66.7% (4 patients) with 3 complete responses, which were durable off therapy. Median follow up was 18.2 months. Median progression free survival (PFS) was 10.2 months [95%confidence interval (95%CI): 1.77, not reached (NR)] and median overall survival (OS) was 18.2 months (95%CI: 12.1, NR). Side effects presented in 4 (66.7%) patients and included hypothyroidism, diarrhea, anemia, thrombocytopenia, rash, and bullous dermatitis. One patient developed grade 3 anemia and no patients experienced grade 4 events or required hospitalization due to treatment side effects., Conclusions: Our experience in a small cohort of patients ≥ 90 years indicate that ICIs are well tolerated and effective for the treatment of advanced urothelial carcinoma in this patient population.

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results